Skip to main content


Table 2 Tissue to plasma exposure ratio of paclitaxel for tumor, liver, and spleen following intravenous administration

From: Nanosuspension delivery of paclitaxel to xenograft mice can alter drug disposition and anti-tumor activity

Tissue to plasma ratio Formulation
  Cremophor EL:ethanol Nanosuspension
Tumor AUC0-8/plasma AUC0-8 0.7 8.3
Liver AUC0-8/plasma AUC0-8 3.6 810.0
Spleen AUC0-8/plasma AUC0-8 1.1 16.8
  1. AUC0-8, area under the concentration-time profile from 0 to 8 h.